234 related articles for article (PubMed ID: 23686481)
1. Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand.
Frazier WR; Steiner N; Hou L; Dakshanamurthy S; Hurley CK
J Immunol; 2013 Jun; 190(12):6198-208. PubMed ID: 23686481
[TBL] [Abstract][Full Text] [Related]
2. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3.
Moesta AK; Norman PJ; Yawata M; Yawata N; Gleimer M; Parham P
J Immunol; 2008 Mar; 180(6):3969-79. PubMed ID: 18322206
[TBL] [Abstract][Full Text] [Related]
3. Structural plasticity of KIR2DL2 and KIR2DL3 enables altered docking geometries atop HLA-C.
Moradi S; Stankovic S; O'Connor GM; Pymm P; MacLachlan BJ; Faoro C; Retière C; Sullivan LC; Saunders PM; Widjaja J; Cox-Livingstone S; Rossjohn J; Brooks AG; Vivian JP
Nat Commun; 2021 Apr; 12(1):2173. PubMed ID: 33846289
[TBL] [Abstract][Full Text] [Related]
4. Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.
Hilton HG; Vago L; Older Aguilar AM; Moesta AK; Graef T; Abi-Rached L; Norman PJ; Guethlein LA; Fleischhauer K; Parham P
J Immunol; 2012 Aug; 189(3):1418-30. PubMed ID: 22772445
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic HLA-C Receptors Balance the Functional Characteristics of KIR Haplotypes.
Hilton HG; Guethlein LA; Goyos A; Nemat-Gorgani N; Bushnell DA; Norman PJ; Parham P
J Immunol; 2015 Oct; 195(7):3160-70. PubMed ID: 26311903
[TBL] [Abstract][Full Text] [Related]
6. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition.
Winter CC; Gumperz JE; Parham P; Long EO; Wagtmann N
J Immunol; 1998 Jul; 161(2):571-7. PubMed ID: 9670929
[TBL] [Abstract][Full Text] [Related]
7. Quantity of HLA-C surface expression and licensing of KIR2DL+ natural killer cells.
Charoudeh HN; Schmied L; Gonzalez A; Terszowski G; Czaja K; Schmitter K; Infanti L; Buser A; Stern M
Immunogenetics; 2012 Oct; 64(10):739-45. PubMed ID: 22772778
[TBL] [Abstract][Full Text] [Related]
8. Combined genotypic and phenotypic killer cell Ig-like receptor analyses reveal KIR2DL3 alleles displaying unexpected monoclonal antibody reactivity: identification of the amino acid residues critical for staining.
Falco M; Romeo E; Marcenaro S; Martini S; Vitale M; Bottino C; Mingari MC; Moretta L; Moretta A; Pende D
J Immunol; 2010 Jul; 185(1):433-41. PubMed ID: 20525888
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility to Crohn's disease is mediated by KIR2DL2/KIR2DL3 heterozygosity and the HLA-C ligand.
Hollenbach JA; Ladner MB; Saeteurn K; Taylor KD; Mei L; Haritunians T; McGovern DP; Erlich HA; Rotter JI; Trachtenberg EA
Immunogenetics; 2009 Oct; 61(10):663-71. PubMed ID: 19789864
[TBL] [Abstract][Full Text] [Related]
10. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation.
David G; Djaoud Z; Willem C; Legrand N; Rettman P; Gagne K; Cesbron A; Retière C
J Immunol; 2013 Nov; 191(9):4778-88. PubMed ID: 24078689
[TBL] [Abstract][Full Text] [Related]
11. KIR2DL2/2DL3-E(35) alleles are functionally stronger than -Q(35) alleles.
Bari R; Thapa R; Bao J; Li Y; Zheng J; Leung W
Sci Rep; 2016 Mar; 6():23689. PubMed ID: 27030405
[TBL] [Abstract][Full Text] [Related]
12. Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals.
Cassidy S; Mukherjee S; Myint TM; Mbiribindi B; North H; Traherne J; Mulder A; Claas FH; Purbhoo MA; Das J; Khakoo SI
Eur J Immunol; 2015 Feb; 45(2):492-500. PubMed ID: 25359276
[TBL] [Abstract][Full Text] [Related]
13. Allelic polymorphism of KIR2DL2/2DL3 in a southern Chinese population.
Zhen J; He L; Xu Y; Zhao J; Yu Q; Zou H; Sun G; Deng Z
Tissue Antigens; 2015 Nov; 86(5):362-7. PubMed ID: 26423800
[TBL] [Abstract][Full Text] [Related]
14. Conjunctival scarring in trachoma is associated with the HLA-C ligand of KIR and is exacerbated by heterozygosity at KIR2DL2/KIR2DL3.
Roberts CH; Molina S; Makalo P; Joof H; Harding-Esch EM; Burr SE; Mabey DC; Bailey RL; Burton MJ; Holland MJ
PLoS Negl Trop Dis; 2014 Mar; 8(3):e2744. PubMed ID: 24651768
[TBL] [Abstract][Full Text] [Related]
15. A single polymorphism disrupts the killer Ig-like receptor 2DL2/2DL3 D1 domain.
VandenBussche CJ; Dakshanamurthy S; Posch PE; Hurley CK
J Immunol; 2006 Oct; 177(8):5347-57. PubMed ID: 17015720
[TBL] [Abstract][Full Text] [Related]
16. Stable Frequencies of HLA-C
Ziegler MC; Grañana FB; Garcia-Beltran WF; Schulze Zur Wiesch J; Hoffmann C; Rechtien A; Lunemann S; Altfeld M
Front Immunol; 2018; 9():2361. PubMed ID: 30386333
[TBL] [Abstract][Full Text] [Related]
17. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition.
Schönberg K; Sribar M; Enczmann J; Fischer JC; Uhrberg M
Blood; 2011 Jan; 117(1):98-107. PubMed ID: 20935255
[TBL] [Abstract][Full Text] [Related]
18. HLA-C and KIR genes in hepatitis C virus infection.
Montes-Cano MA; Caro-Oleas JL; Romero-Gómez M; Diago M; Andrade R; Carmona I; Aguilar Reina J; Núñez-Roldán A; González-Escribano MF
Hum Immunol; 2005 Nov; 66(11):1106-9. PubMed ID: 16571411
[TBL] [Abstract][Full Text] [Related]
19. Peptide antagonism as a mechanism for NK cell activation.
Fadda L; Borhis G; Ahmed P; Cheent K; Pageon SV; Cazaly A; Stathopoulos S; Middleton D; Mulder A; Claas FH; Elliott T; Davis DM; Purbhoo MA; Khakoo SI
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10160-5. PubMed ID: 20439706
[TBL] [Abstract][Full Text] [Related]
20. Killer immunoglobulin receptor genes and their HLA-C ligand are associated with Type 1 diabetes in an Eastern Indian population.
Sanjeevi S; Sun C; Kanungo A; Sanjeevi CB
Diabet Med; 2016 Jan; 33(1):91-6. PubMed ID: 26031759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
